Patents by Inventor Tsann Ming Chu

Tsann Ming Chu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of use of a ductal carcinoma antigen
    Patent number: 5871936
    Abstract: Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: February 16, 1999
    Assignee: Health Research, Inc.
    Inventors: Tsann Ming Chu, Lawrence D. Papsidero
  • Purified ductal carcinoma antigen
    Patent number: 5798445
    Abstract: Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.
    Type: Grant
    Filed: October 17, 1996
    Date of Patent: August 25, 1998
    Assignee: Health Research, Inc.
    Inventors: Tsann Ming Chu, Lawrence D. Papsidero
  • Diagnostic immunoassay methods using monoclonal antibody F36/22 which is specific for human breast carcinoma cells
    Patent number: 5652114
    Abstract: Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid human breast tumors xenografted in nude mice. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.
    Type: Grant
    Filed: September 18, 1989
    Date of Patent: July 29, 1997
    Assignee: Health Research Inc.
    Inventors: Tsann Ming Chu, Lawrence D. Papsidero, Gary A. Croghan